Calidi Biotherapeutics FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000

Reuters

Yesterday

<a href="https://laohu8.com/S/CLDI">Calidi Biotherapeutics</a> FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000

Calidi published a press release reporting fourth-quarter and full-year 2025 financial results and recent operational updates.
Net loss attributable to common stockholders was USD 4.1 million for Q4, or USD 0.57 per share.
R&D expense rose 33.33% to USD 2.4 million in Q4, while G&A expense fell 4.55% to USD 2.1 million.
Net loss attributable to common stockholders was USD 25.6 million for FY 2025, or USD 5.95 per share.
Cash was USD 5.6 million at Dec. 31, 2025, and the company said it expects to file an IND for CLD-401 by end of 2026 after FDA Type D interactions and partnerships with Avance Clinical and Matica Bio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271625PRIMZONEFULLFEED9680081) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2622808985"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622808985\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622808985?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622808985","market":"fut","top_or_hot":-1,"title":"Calidi Biotherapeutics FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLDI\">Calidi Biotherapeutics</a> FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Calidi published a press release reporting fourth-quarter and full-year 2025 financial results and recent operational updates.\n        </li>\n<li>\n          Net loss attributable to common stockholders was USD 4.1 million for Q4, or USD 0.57 per share.\n        </li>\n<li>\n          R&amp;D expense rose 33.33% to USD 2.4 million in Q4, while G&amp;A expense fell 4.55% to USD 2.1 million.\n        </li>\n<li>\n          Net loss attributable to common stockholders was USD 25.6 million for FY 2025, or USD 5.95 per share.\n        </li>\n<li>\n          Cash was USD 5.6 million at Dec. 31, 2025, and the company said it expects to file an IND for CLD-401 by end of 2026 after FDA Type D interactions and partnerships with Avance Clinical and Matica Bio.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CLDWW\">Calidi Biotherapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271625PRIMZONEFULLFEED9680081) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Calidi Biotherapeutics FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalidi Biotherapeutics FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-28 04:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLDI\">Calidi Biotherapeutics</a> FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Calidi published a press release reporting fourth-quarter and full-year 2025 financial results and recent operational updates.\n        </li>\n<li>\n          Net loss attributable to common stockholders was USD 4.1 million for Q4, or USD 0.57 per share.\n        </li>\n<li>\n          R&amp;D expense rose 33.33% to USD 2.4 million in Q4, while G&amp;A expense fell 4.55% to USD 2.1 million.\n        </li>\n<li>\n          Net loss attributable to common stockholders was USD 25.6 million for FY 2025, or USD 5.95 per share.\n        </li>\n<li>\n          Cash was USD 5.6 million at Dec. 31, 2025, and the company said it expects to file an IND for CLD-401 by end of 2026 after FDA Type D interactions and partnerships with Avance Clinical and Matica Bio.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CLDWW\">Calidi Biotherapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271625PRIMZONEFULLFEED9680081) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014005.SGD","symbol_name":"United Global Durable Equities Fund Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8W50W3:1","article_id":"2622808985","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622808985","pubTimestamp":1774643151,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Calidi published a press release reporting fourth-quarter and full-year 2025 financial results and recent operational updates.Net loss attributable to common stockholders was USD 4.1 million for Q4, or USD 0.57 per share.R&D expense rose 33.33% to USD 2.4 million in Q4, while G&A expense fell 4.55% to USD 2.1 million.Net loss attributable to common stockholders was USD 25.6 million for FY 2025, or USD 5.95 per share.Cash was USD 5.6 million at Dec. 31, 2025, and the company said it expects to file an IND for CLD-401 by end of 2026 after FDA Type D interactions and partnerships with Avance Clinical and Matica Bio.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4139":"生物科技","CLDI":"CALIDI BIOTHERAPEUTICS INC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Calidi Biotherapeutics 2025财年每股亏损收窄83.33%至5.95美元；收入下降41.67%至50,000美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDI":0.9,"NDAQ":0.9},"content_text":"Calidi Biotherapeutics FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000\n    \n\n\n          Calidi published a press release reporting fourth-quarter and full-year 2025 financial results and recent operational updates.\n        \n\n          Net loss attributable to common stockholders was USD 4.1 million for Q4, or USD 0.57 per share.\n        \n\n          R&D expense rose 33.33% to USD 2.4 million in Q4, while G&A expense fell 4.55% to USD 2.1 million.\n        \n\n          Net loss attributable to common stockholders was USD 25.6 million for FY 2025, or USD 5.95 per share.\n        \n\n          Cash was USD 5.6 million at Dec. 31, 2025, and the company said it expects to file an IND for CLD-401 by end of 2026 after FDA Type D interactions and partnerships with Avance Clinical and Matica Bio.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271625PRIMZONEFULLFEED9680081) on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}